Screening for sleep-disordered breathing in people with type 1 diabetes by combining polysomnography with glucose variability assessment.

Aims: There are few published data on sleep-disordered breathing (SDB) in type 1 diabetes (T1DM). Here, we used a combination of polysomnography and glucose variability assessment to screen for SDB.

Methods: In a prospective, single-centre study, adults with T1DM underwent polysomnography and continuous glucose monitoring during a single night.

Control of disease activity and tumor size after introduction of pegvisomant in a lanreotide-resistant acromegalic patient.

We report on a 30-year-old female acromegalic patient treated with the growth hormone (GH) receptor antagonist pegvisomant at a low dose after the failure of long-acting lanreotide, neurosurgery and radiotherapy treatment to restore IGF-1 levels. The combination treatment was well tolerated and produced a dramatic improvement in the patient's condition (reduction in visual field defects, relief of headache and excessive perspiration), normalization of IGF-I levels and a considerable decrease in tumor size, enabling a dramatic decrease in lanreotide dosage and, ultimately, its withdrawal.

Nocturnal hyperglycaemia in type 2 diabetes with sleep apnoea syndrome.

We assessed glycaemic status in 26 overweight or obese people with type 2 diabetes suspected of having sleep apnoea syndrome (SAS). In people with SAS (n=13), nocturnal glycaemia was 38% higher, independent of body mass index (particularly during rapid eye movement sleep) compared with non-SAS subjects (p<0.008).